A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer-Reference-Cited by-同舟云学术

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer

Published:2014-03-18 Issue:8 Volume:110 Page:1923-1929
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Glasspool R M,Brown R,Gore M E,Rustin G J S,McNeish I A,Wilson R H,Pledge S,Paul J,Mackean M,Hall G D,Gabra H,Halford S E R,Walker J,Appleton K,Ullah R,Kaye S

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2014116.pdf

Reference23 articles.

1. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schätzlein A, Twelves C, Kaye SB, Brown R (2007) Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25: 4603–4609.

2. Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG, Anthoney DA (1997) hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15: 45–52.

3. Chang X, Monitto CL, Demokan S, Kim MS, Chang SS, Zhong X, Califano JA, Sidransky D (2010) Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res 70: 2870–2879.

4. Dai W, Teodoridis JM, Graham J, Zeller C, Huang TH, Yan P, Vass JK, Brown R, Paul J (2008) Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands. BMC Bioinformatics 9: 337.

5. Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP, Matei DE (2010) A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 116: 4043–4053.

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repression of LSD1/KDM1A activity improves the response of liver cancer cells to the lenvatinib;Discover Oncology;2024-03-28

2. Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-03

3. A Comprehensive Review on Current Treatments and Challenges Involved in the Treatment of Ovarian Cancer;Current Cancer Drug Targets;2024-02

4. The Interplay Between HIF‐1α and EZH2 in Lung Cancer and Dual‐Targeted Drug Therapy;Advanced Science;2023-12-10

5. Molecular Mechanism of Multi‐Drug Resistant Cancer Cells;Multi‐Drug Resistance in Cancer;2023-07-17